Vabysmo®
GoodRxFaricimab · intravitreal injection
Injections & Implants
Approved uses
Neovascular (wet) age-related macular degeneration and diabetic macular edema
6 mg (0.05 mL of 120 mg/mL) intravitreally every 4 weeks for the first 4 doses, then extended on OCT and acuity response up to every 16 weeks
Dual VEGF-A and angiopoietin-2 inhibition, which is what allows the extended interval
Macular edema following retinal vein occlusion
6 mg (0.05 mL of 120 mg/mL) intravitreally every 4 weeks
Contraindications
Ocular or periocular infection Active intraocular inflammation Hypersensitivity.
Available FormsIntravitreal injection, 6 mg (0.05 mL of 120 mg/mL) in a single-dose prefilled syringe or single-dose vial.
Mechanism of ActionFaricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.
Warnings & Precautions
Endophthalmitis and retinal detachment may follow intravitreal injection; instruct patients to report suggestive symptoms without delay. Increases in intraocular pressure have been seen after injection. There is a potential risk of arterial thromboembolic events.
Common Side Effects
The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).
Pregnancy & LactationPregnancy: No adequate and well-controlled studies in pregnant women. Faricimab given to pregnant monkeys throughout organogenesis increased abortion and embryofetal death at systemic exposures above those expected from intravitreal dosing. Advise a woman of reproductive potential to use effective contraception during treatment and for three months after the last dose.
Lactation: No data on presence in human milk or effects on the breastfed infant.
Pediatric UseThe safety and efficacy of VABYSMO in pediatric patients have not been established.